143 related articles for article (PubMed ID: 33117662)
1. Correlation Between Psoriasis Severity and Nonalcoholic Fatty Liver Disease Degree Measured Using Controlled Attenuation Parameter.
Gandha N; Wibawa LP; Jacoeb TNA; Sulaiman AS
Psoriasis (Auckl); 2020; 10():39-44. PubMed ID: 33117662
[TBL] [Abstract][Full Text] [Related]
2. The Association Between Chronic Plaque Psoriasis and Nonalcoholic Fatty Liver Disease in Indian Patients: Results of a Pilot Study.
Mahajan VK; Chauhan NS; Rana BS; Mehta KS; Hooda S; Chauhan PS; Kukreja A
J Clin Exp Hepatol; 2022; 12(3):785-792. PubMed ID: 35677516
[TBL] [Abstract][Full Text] [Related]
3. Interleukin Levels and Non-Alcoholic Fatty Liver Disease in Chronic Plaque Psoriasis: An Analytical Case Control Study.
Yadav V; Mendiratta V; Agrawal A; Bisherwal K; Singh R; Meena AK
Indian J Dermatol; 2023; 68(4):377-384. PubMed ID: 37822394
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic Fatty Liver Disease Among Iraqi Patients With Psoriasis: A Case-Control Study.
Dhaher SA; Hilfi NZ; Abdullah MA
Cureus; 2024 Apr; 16(4):e57487. PubMed ID: 38707119
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the correlation between scales determining disease severity in patients with moderate-severe chronic plaque-type psoriasis.
Gundogdu M; Kundakci N
J Cosmet Dermatol; 2021 Jul; 20(7):2328-2331. PubMed ID: 33142051
[TBL] [Abstract][Full Text] [Related]
6. Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease.
Ahn JM; Paik YH; Min SY; Cho JY; Sohn W; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut Liver; 2016 Mar; 10(2):295-302. PubMed ID: 26347511
[TBL] [Abstract][Full Text] [Related]
7. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease.
Abedini R; Salehi M; Lajevardi V; Beygi S
Clin Exp Dermatol; 2015 Oct; 40(7):722-7. PubMed ID: 25958919
[TBL] [Abstract][Full Text] [Related]
8. Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis.
Fujimori N; Tanaka N; Shibata S; Sano K; Yamazaki T; Sekiguchi T; Kitabatake H; Ichikawa Y; Kimura T; Komatsu M; Umemura T; Matsumoto A; Tanaka E
Hepatol Res; 2016 Sep; 46(10):1019-27. PubMed ID: 27183219
[TBL] [Abstract][Full Text] [Related]
9. The role of non-invasive scores in determining the liver fibrosis in NAFLD and psoriatic patients.
Neagoe CD; Farmazon AS; Amzolini AM; Singer CE; Ianoşi SL; Tutunaru CV; Genunche-Dumitrescu AV; Ianoşi NG; Păun I; Leru PM; Tica OS; Popescu M
Rom J Morphol Embryol; 2020; 61(2):503-511. PubMed ID: 33544802
[TBL] [Abstract][Full Text] [Related]
10. Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire.
Barrea L; Macchia PE; Tarantino G; Di Somma C; Pane E; Balato N; Napolitano M; Colao A; Savastano S
J Transl Med; 2015 Sep; 13():303. PubMed ID: 26376719
[TBL] [Abstract][Full Text] [Related]
11. Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease.
Shrestha R; Kc S; Thapa P; Pokharel A; Karki N; Jaishi B
Cureus; 2021 Jul; 13(7):e16414. PubMed ID: 34422459
[TBL] [Abstract][Full Text] [Related]
12. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
Bruins FM; Bronckers IMGJ; Groenewoud HMM; van de Kerkhof PCM; de Jong EMGJ; Seyger MMB
JAMA Dermatol; 2020 Jan; 156(1):72-78. PubMed ID: 31774449
[TBL] [Abstract][Full Text] [Related]
13. A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis.
Awosika O; Eleryan MG; Rengifo-Pardo M; Doherty L; Martin LW; Ehrlich A
J Clin Aesthet Dermatol; 2018 Jun; 11(6):33-37. PubMed ID: 29942422
[No Abstract] [Full Text] [Related]
14. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.
Walsh JA; McFadden M; Woodcock J; Clegg DO; Helliwell P; Dommasch E; Gelfand JM; Krueger GG; Duffin KC
J Am Acad Dermatol; 2013 Dec; 69(6):931-7. PubMed ID: 24054760
[TBL] [Abstract][Full Text] [Related]
15. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
16. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
17. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
Jacobson CC; Kimball AB
Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin for the treatment of plaque-type psoriasis.
Faghihi T; Radfar M; Mehrabian Z; Ehsani AH; Rezaei Hemami M
Pharmacotherapy; 2011 Nov; 31(11):1045-50. PubMed ID: 22026392
[TBL] [Abstract][Full Text] [Related]
19. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
Bożek A; Reich A
Adv Clin Exp Med; 2017 Aug; 26(5):851-856. PubMed ID: 29068583
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study.
van der Voort EA; Koehler EM; Dowlatshahi EA; Hofman A; Stricker BH; Janssen HL; Schouten JN; Nijsten T
J Am Acad Dermatol; 2014 Mar; 70(3):517-24. PubMed ID: 24373781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
